**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 55559

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Significance of serum** **fibroblast growth factor-23 and miR-208b** **in pathogenesis of atrial fibrillation and their relationship with prognosis**

Chen JM *et al*. FGF-23 and miR-208b in pathogenesis of atrial fibrillation

Jie-Min Chen, Yao-Tang Zhong, Chang Tu, Jun Lan

**Jie-Min Chen, Yao-Tang Zhong, Chang Tu, Jun Lan,** Department of Cardiovascular Medicine, Dongguan Songshan Lake Central Hospital, Dongguan Institute of Cardiovascular Disease, Dongguan 523326, Guangdong Province, China

**Author contributions:** Chen JM and Zhong YT designed this retrospective study; Chen JM wrote this paper; Tu C was responsible for sorting the data.

**Corresponding author: Jun Lan, MD, Chief Physician,** Department of Cardiovascular Medicine, Dongguan Songshan Lake Central Hospital, Dongguan Institute of Cardiovascular Disease, No. 1, Xianglong Road, Dongguan 523326, Guangdong Province, China. [dglanjun@163.com](mailto:dglanjun@163.com)

**Received:** April 9, 2020

**Revised:** May 12, 2020

**Accepted:** July 14, 2020

**Published online:** August 26, 2020

**Abstract**

BACKGROUND

The incidence and prevalence of atrial fibrillation are increasing each year, and this condition is one of the most common clinical arrhythmias.

AIM

To investigate the levels and significance of serum fibroblast growth factor 23 (FGF-23) and miR-208b in patients with atrial fibrillation and their relationship with prognosis.

METHODS

From May 2018 to October 2019, 240 patients with atrial fibrillation were selected as an observation group, including 134 with paroxysmal atrial fibrillation and 106 with persistent atrial fibrillation; 150 patients with healthy sinus rhythm were selected as a control group. The serum levels of FGF-23 and miR-208b in the two groups were measured. In the observation group, cardiac parameters were determined by echocardiography.

RESULTS

The serum levels of FGF-23 and miR-208b in the observation group were 210.20 ± 89.60 ng/mL and 5.30 ± 1.22 ng/mL, which were significantly higher than the corresponding values in the control group (*P* < 0.05). In the observation group, the serum levels of FGF-23 and miR-208b in patients with persistent atrial fibrillation were 234.22 ± 70.05 ng/mL and 5.83 ± 1.00 ng/mL, which were significantly higher than the corresponding values in patients with paroxysmal atrial fibrillation (*P* < 0.05). The left atrial dimension (LAD) of patients with persistent atrial fibrillation was 38.81 ± 5.11 mm, which was significantly higher than that of patients with paroxysmal atrial fibrillation (*P* > 0.05). The serum levels of FGF-23 and miR-208b were positively correlated with the LAD (*r* = 0.411 and 0.382, *P* < 0.05). In the observation group, the serum levels of FGF-23 and miR-208b in patients with a major cardiovascular event (MACE) were 243.30 ± 72.29 ng/mL and 6.12 ± 1.12 ng/mL, which were significantly higher than the corresponding values in patients without a MACE (*P* < 0.05).

CONCLUSION

The serum levels of FGF-23 and miR-208b are increased in patients with atrial fibrillation and are related to the type of disease, cardiac parameters, and prognosis.

**Key words:** Fibroblast growth factor-23; MiR-208b; Atrial fibrillation; Prognosis

**Citation:** ChenJM, Zhong YT, Tu C, Lan J. Significance of serum fibroblast growth factor-23 and miR-208b in the pathogenesis of atrial fibrillation and their relationship with prognosis. *World J Clin Cases* 2020; 8(16): 3458-3464

**URL:** https://www.wjgnet.com/2307-8960/full/v8/i16/3458.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v8.i16.3458

**Core tip:** In this study, the authors investigated the levels and significance of serum fibroblast growth factor 23 and miR-208b in patients with atrial fibrillation and their relationship with prognosis.

**INTRODUCTION**

The incidence and prevalence of atrial fibrillation are increasing each year, and this condition is one of the most common clinical arrhythmias[1,2]. Atrial fibrillation leads to stroke, thromboembolic events, heart failure, myocardial infarction, and cognitive decline, as well as an increased risk of chronic kidney disease and other diseases[3]. The identification of useful serological markers can provide guidance for the primary prevention of atrial fibrillation and for monitoring and evaluating treatment efficacy and prognosis[4]. Fibroblast growth factor 23 (FGF-23) is a member of the FGF superfamily and is closely related to the development of cardiovascular disease[5]. Most microRNAs (miRNAs) exhibit tissue specificity and are stable in serum, making them potential biomarkers for disease diagnosis[6]. MiR-208b was found in the plasma of patients with acute myocardial infarction, which indicates that heart-specific miR-208b can be released from damaged cardiomyocytes into the blood circulation[7]. The present study aimed to investigate the levels and significance of serum FGF-23 and miR-208b in patients with atrial fibrillation and their relevance to patient prognosis.

**MATERIALS AND METHODS**

***General information***

In total, 240 patients with atrial fibrillation treated at our hospital from May 2018 to October 2019 were selected as an observation group, including 134 patients with paroxysmal atrial fibrillation and 106 with persistent atrial fibrillation. The inclusion criteria were as follows: (1) Diagnosis with atrial fibrillation according to the diagnostic criteria of the 2016 ESC atrial fibrillation management guidelines; (2) cardiac function NYHA grade I-III; and (3) complete clinical follow-up data. The exclusion criteria were as follows: (1) Heart diseases such as valvular heart disease; (2) malignant tumors, immune system diseases, circulatory system diseases, and other diseases; and (3) history of infection within the past month. At the same time, 150 patients with normal sinus rhythm as determined by clinical examination were selected as a control group, and general data for the observation group and control group are compared in Table 1.

***Detection methods***

Three milliliters of venous blood was taken at each time point, placed into an EDTA anticoagulant tube, and centrifuged at 2000 r/min at 4 °C for 20 min; then, the supernatant was removed and stored at -80 °C. Real-time quantitative PCR (qRT-PCR) was used to detect miR-208b in serum. For total RNA extraction, the serum was placed in an RNase-free centrifuge tube, the lysis buffer was added, and the solution was mixed thoroughly to lyse the cells according to the kit instructions. The RNA concentration and purity were detected according to spectrophotometry. RNA was then used for cDNA synthesis. Reverse transcription was performed in a reaction system containing 2 μL of RNA template, 2 μL of RT primer, 5 µL of 5 × RT buffer, 2 μL of dNTP (2.5 mmol/L), 0.5 μL of RNase inhibitor (40 U/µL), 0.5 µL of reverse transcriptase (20 U/µL), and 24 µL of ddH2O. cDNA was generated following the steps in the reverse transcription kit. qRT-PCR was then performed in a 20-μL reaction system containing 2 μL of cDNA, 10 µL of 2 × SYBR Green qPCR mixture, 1 µL of forward primer, 1 µL of reverse primer, and 6 µL of diethylpyrocarbonate-treated water. Each target gene was analyzed in triplicate with the following cycling conditions: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 min, 60 °C for 1 min, and 72 °C for 30 s. The qRT-PCR instrument was programmed for PCR amplification, and the 2-ΔΔCT method was used to calculate the relative expression of miR-208b. β-actin was used as the internal reference gene.

Five milliliters of venous blood was collected from the middle of the elbow vein of fasted patients on the morning after admission. After 20 min of natural condensation, serum was isolated within 2 h after blood collection by centrifugation at 3000 r/min for 10 min. The isolated supernatant was stored in an Eppendorf tube at -80 °C. The serum FGF-23 concentration was detected by enzyme-linked immunosorbent assay.

Cardiac function and structural indexes were determined using a DW-CE540 color Doppler ultrasound instrument (Dawei Medical Co., Ltd.) and an S5-1 probe with a frequency of 2-5 MHz. The patient was placed in the left lateral position, with the left ventricle near the long axis of the sternum. We measured the left ventricular systolic diameter, left ventricular end diastolic diameter (LVEDD), left ventricular dysfunction, and the distance from the left posterior wall of the atrium to the front wall of the left atrium and the back of the aorta. The apical four-chamber and two-chamber heart sections were adopted, and the left ventricular ejection fraction (LVEF) was calculated using Simpson’s method. The values were continuously evaluated for 5 to 7 cardiac cycles, and the average was recorded.

***Statistical analysis***

The data were analyzed with SPSS 22.0 software and are reported as the mean ± SEM or *n* (%), as appropriate. The *χ*2 test and analysis of differences were used to compare groups, and Pearson’s correlation analysis was used to identify correlations. Differences were considered statistically significant at *P* < 0.05.

**RESULTS**

***Comparison of serum FGF-23 and miR-208b levels in the two groups***

The relative levels of serum FGF-23 and miR-208b in the observation group were significantly higher than those in the control group (*P* < 0.05, Table 2).

***Comparison of serum FGF-23 and miR-208b levels and cardiac parameters in different subgroups of the observation group***

In the observation group, the relative levels of serum FGF-23 and miR-208b in patients with persistent atrial fibrillation were significantly higher than those in patients with paroxysmal atrial fibrillation (*P* < 0.05), and the LAD was significantly higher in patients with persistent atrial fibrillation than in patients with paroxysmal atrial fibrillation (*P* > 0.05, Table 3).

***Correlation analysis***

The relative levels of serum FGF-23 and miR-208b were analyzed for correlations with the LAD, and the results showed a positive correlation (*r* = 0.411 and *r* = 0.382, *P* < 0.05).

***Comparison of serum FGF-23 and miR-208b among patients in the observation group with different prognoses***

Patients were grouped based on the occurrence of a major cardiovascular event (MACE) (*n* = 58) or not (*n* = 182) during follow-up. MACEs included cardiogenic death, nonfatal myocardial infarction, heart failure, readmission due to recurrence, *etc*. The serum FGF-23 and miR-208b levels in the MACE group were 243.30 ± 72.29 ng/mL and 6.12 ± 1.12 ng/mL, respectively, and these values were significantly higher than those in patients without a MACE (*P* < 0.05, Table 4).

**DISCUSSION**

The mechanisms of atrial fibrillation occurrence and maintenance are complex. The electrical pulse from the pulmonary ectopic excitatory focus is considered an important mechanism of atrial fibrillation, and atrial fibrosis is considered an important factor in the difficulty of maintaining and sustaining atrial fibrillation[8-10]. It is important to identify biomarkers with a high specificity and sensitivity. Cardiovascular diseases are usually accompanied by changes in miRNA levels in the peripheral circulation. Acute obstruction of the coronary artery disrupts blood flow, causing ischemia, death, heart failure, and cardiomyocyte death; therefore, early diagnosis and effective treatment are vitally important to improve patient prognosis[11,12].

FGF-23 requires binding to FGF receptors to exert biological activity, and relies on the alpha-Klotho protein as a coreceptor[13]. The alpha-Klotho protein shows tissue-specific expression with predominant distribution in the kidney and parathyroid glands. It is the main target organ of FGF-23[14]. FGF-23 is linked to the onset of many cardiovascular diseases, and current research has confirmed[15] that elevated levels of FGF-23 are significantly associated with left ventricular hypertrophy, hypertension, cardiogenic death, and all-cause death. Research shows[16] that high levels of FGF-23 are an independent predictor of cardiovascular events. However, there are few reports on the relationship between FGF-23 levels and atrial fibrillation.

MiRNA levels typically change in the peripheral circulation of patients with heart failure, myocardial infarction, coronary heart disease, and other cardiovascular diseases. Both miR-208a and miR-208b are cardiac tissue-specific miRNAs[17]. The results of this study showed that the relative levels of serum FGF-23 and miR-208b were significantly higher in the observation group than in the control group; besides, both levels were higher in patients with a MACE and changed significantly as the patient's condition deteriorated, suggesting that high FGF-23 levels in patients with atrial fibrillation are closely related to the maintenance of this condition. The increases in FGF-23 and miR-208b may be associated with factors such as atrial overload, atrial systolic dysfunction, and decreased cardiac function. Factors such as FGF-23 and miR-208b may act as independent predictors of adverse events in patients with atrial fibrillation. The mechanism of FGF-23 involves increasing the sodium current in atrial myocytes by activating the protein kinase C signal transduction pathway. The L-type calcium current and calcium transients lead to calcium and sodium imbalance. Through the oxidative stress pathway, there is excessive formation of mitochondrial reactive oxygen species in cardiomyocytes, which increases the incidence of arrhythmia originating in the pulmonary vein.

LAD, LVEDD, left ventricular end-systolic diameter, and LVEF may reflect the severity of atrial fibrillation[7,18]. The results of this study showed that patients with atrial fibrillation had an elevated LAD and a corresponding increase in the severity of atrial fibrillation, similar to the effects of previous studies, suggesting that the LAD may be a risk factor for the occurrence and severity of atrial fibrillation. Potential reasons for this association are that inflammatory-mediated atrial structural remodeling and electrical remodeling in patients with atrial fibrillation may be essential factors for the maintenance and development of atrial fibrillation. The extent of left atrial enlargement is closely related to the recurrence of atrial fibrillation and thrombosis. Studies show[19,20] that the occurrence and development of atrial fibrillation are influenced by many mechanisms and factors, especially those related to left atrial structural remodeling and electrophysiological modifications. This study not only examined the changes in cardiac parameters of the LAD but also compared the changes in serum FGF-23 and miR-208b in different patients; these factors were found to be related to the severity of atrial fibrillation, and our findings are helpful for the diagnosis, evaluation, and prognosis of patients with atrial fibrillation. However, this test also has some defects, such as failure to reveal the relationship between these factors and the linearity of atrial fibrillation or some other aspects. For this, we need to further conduct a large number of experiments

In summary, serum FGF-23 and miR-208b levels are elevated in patients with atrial fibrillation and correlate with disease type, cardiac parameters, and prognosis.

**ARTICLE HIGHLIGHTS**

***Research background***

The incidence and prevalence of atrial fibrillation are increasing each year, and this condition is one of the most common clinical arrhythmias

***Research motivation***

The identification of useful serological markers can provide guidance for the primary prevention of atrial fibrillation and for monitoring and evaluating treatment efficacy and prognosis

***Research objectives***

To investigate the levels and significance of serum fibroblast growth factor (FGF)-23 and miR-208b in atrial fibrillation and their relevance to patient prognosis

***Research methods***

A total of 240 patients with atrial fibrillation treated at our hospital from May 2018 to October 2019 were included.

***Research results***

The serum levels of FGF-23 and miR-208b in the observation group were significantly higher than the corresponding values in the control group. In the observation group, the serum levels of FGF-23 and miR-208b in patients with persistent atrial fibrillation were significantly higher than those in patients with paroxysmal atrial fibrillation. The left atrial dimension (LAD) of patients with persistent atrial fibrillation was significantly higher than that of patients with paroxysmal atrial fibrillation. The serum levels of FGF-23 and miR-208b were positively correlated with the LAD. In the observation group, the serum levels of FGF-23 and miR-208b in patients with a major cardiovascular event (MACE) were significantly higher than the corresponding values in patients without a MACE.

***Research conclusions***

Serum FGF-23 and miR-208b levels are elevated in patients with atrial fibrillation and correlate with disease type, cardiac parameters, and prognosis.

***Research perspectives***

Our findings may suggest a new method for evaluating the condition of atrial fibrillation.

**REFERENCES**

1 **Liu L**, Zhang H, Mao H, Li X, Hu Y. Exosomal miR-320d derived from adipose tissue-derived MSCs inhibits apoptosis in cardiomyocytes with atrial fibrillation (AF). *Artif Cells Nanomed Biotechnol* 2019; **47**: 3976-3984 [PMID: 31591913 DOI: 10.1080/21691401.2019.1671432]

2 **Scardigli M**, Cannazzaro S, Coppini R, Crocini C, Yan P, Loew LM, Sartiani L, Cerbai E, Pavone FS, Sacconi L, Ferrantini C. Arrhythmia susceptibility in a rat model of acute atrial dilation. *Prog Biophys Mol Biol* 2020; **154**: 21-29 [PMID: 32063273 DOI: 10.1016/j.pbiomolbio.2019.08.012]

3 **Sethi NJ**, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC. Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. *PLoS One* 2018; **13**: e0193924 [PMID: 29518134 DOI: 10.1371/journal.pone.0193924]

4 **Pastori D**, Lip GYH, Farcomeni A, Del Sole F, Sciacqua A, Perticone F, Marcucci R, Grifoni E, Pignatelli P, Violi F; ATHERO-AF study group. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. *Int J Cardiol* 2018; **264**: 58-63 [PMID: 29776574 DOI: 10.1016/j.ijcard.2018.01.097]

5 **Li YG**, Pastori D, Lip GYH. Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. *Ann Med* 2018; **50**: 288-302 [PMID: 29608110 DOI: 10.1080/07853890.2018.1460489]

6 **Chen C**, Meng Z, Zheng Y, Hu B, Shen E. Fibroblast growth factor 21 inhibition aggravates cardiac dysfunction in diabetic cardiomyopathy by improving lipid accumulation. *Exp Ther Med* 2018; **15**: 75-84 [PMID: 29375676 DOI: 10.3892/etm.2017.5375]

7 **Chen SC**, Chung FP, Chao TF, Hu YF, Lin YJ, Chang SL, Lo LW, Tuan TC, Te ALD, Yamada S, Prabhu A, Chang TY, Lin CY, Chen SA. A link between bilirubin levels and atrial fibrillation recurrence after catheter ablation. *J Chin Med Assoc* 2019; **82**: 175-178 [PMID: 30913114 DOI: 10.1097/JCMA.0000000000000026]

8 **Jiang YQ**, Tian Y, Zeng LJ, He SN, Zheng ZT, Shi L, Wang YJ, Wang YX, Yin XD, Liu XQ, Yang XC, Liu XP. The safety and efficacy of hybrid ablation for the treatment of atrial fibrillation: A meta-analysis. *PLoS One* 2018; **13**: e0190170 [PMID: 29298352 DOI: 10.1371/journal.pone.0190170]

9 **Zhou W**, Wang T, Zhu LJ, Wen MH, Hu LH, Huang X, You CJ, Li JX, Wu YQ, Wu QH, Bao HH, Cheng XS. Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study. *Chin Med J (Engl)* 2019; **132**: 2150-2156 [PMID: 31490268 DOI: 10.1097/CM9.0000000000000423]

10 **Macle L**, Frame D, Gache LM, Monir G, Pollak SJ, Boo LM. Atrial fibrillation ablation with a spring sensor-irrigated contact force-sensing catheter compared with other ablation catheters: systematic literature review and meta-analysis. *BMJ Open* 2019; **9**: e023775 [PMID: 31189669 DOI: 10.1136/bmjopen-2018-023775]

11 **Huang HY**, Lin SY, Cheng SH, Wang CC. Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study. *Sci Rep* 2018; **8**: 3451 [PMID: 29472623 DOI: 10.1038/s41598-018-21884-y]

12 **Bosch NA**, Cohen DM, Walkey AJ. Risk Factors for New-Onset Atrial Fibrillation in Patients With Sepsis: A Systematic Review and Meta-Analysis. *Crit Care Med* 2019; **47**: 280-287 [PMID: 30653473 DOI: 10.1097/CCM.0000000000003560]

13 **Nishimura M**, Hsu JC. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. *Am J Cardiol* 2018; **121**: 131-140 [PMID: 29132650 DOI: 10.1016/j.amjcard.2017.09.030]

14 **Patti G**. Patients with atrial fibrillation and coronary events: are we any closer to coming out from the labyrinth of the various antithrombotic strategies? *Heart* 2018; **104**: 878-879 [PMID: 29175977 DOI: 10.1136/heartjnl-2017-312576]

15 **Rakhshan M**, Najafi H, Valizadeh GA. Lifestyle of Patients with Atrial Fibrillation Following Self-Management Interventions: a Randomized Clinical Trial. *J Caring Sci* 2019; **8**: 83-88 [PMID: 31249817 DOI: 10.15171/jcs.2019.012]

16 **Gao L**, Moodie M. Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure. *BMJ Open* 2019; **9**: e031033 [PMID: 31492790 DOI: 10.1136/bmjopen-2019-031033]

17 **Sun YJ**, Yin XM, Cong T, Gao LJ, Chang D, Xiao XJ, Sun QB, Zhang RF, Yu XH, Dong YX, Yang YZ, Xia YL. Comparison of cryoballoon ablation for atrial fibrillation guided by real-time three-dimensional transesophageal echocardiography vs. contrast agent injection. *Chin Med J (Engl)* 2019; **132**: 285-293 [PMID: 30681494 DOI: 10.1097/CM9.0000000000000076]

18 **Qiu H**, Ji C, Wu H, Zou C. Chronic kidney disease-induced atrial structural remodeling and atrial fibrillation: more studies on the pathological mechanism are encouraged. *Naunyn Schmiedebergs Arch Pharmacol* 2018; **391**: 671-673 [PMID: 29744559 DOI: 10.1007/s00210-018-1494-4]

19 **Avula UMR**, Hernandez JJ, Yamazaki M, Valdivia CR, Chu A, Rojas-Pena A, Kaur K, Ramos-Mondragón R, Anumonwo JM, Nattel S, Valdivia HH, Kalifa J. Atrial Infarction-Induced Spontaneous Focal Discharges and Atrial Fibrillation in Sheep: Role of Dantrolene-Sensitive Aberrant Ryanodine Receptor Calcium Release. *Circ Arrhythm Electrophysiol* 2018; **11**: e005659 [PMID: 29540372 DOI: 10.1161/CIRCEP.117.005659]

20 **Di Monaco A**, Quadrini F, Troisi F, Vitulano N, Cecere G, Guida P, Langialonga T, Grimaldi M. Bilateral left lateral ridge ablation increases the long-term success of patients ablated for atrial fibrillation. *J Cardiovasc Med (Hagerstown)* 2019; **20**: 186-191 [PMID: 30762661 DOI: 10.2459/JCM.0000000000000779]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the Dongguan Songshan Lake Central Hospital.

**Informed consent statement:** Informed consent was obtained from the patients.

**Conflict-of-interest statement:** Dr. Lan J reports a grant from Dongguan Social Science and Technology Development Project (No. 2015108101025) during the conduct of the study. Other authors have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** April 9, 2020

**First decision:** April 29, 2020

**Article in press:** July 14, 2020

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Avalos-Gonzalez J, McHenry H **S-Editor:** Wang JL **L-Editor:** Wang TQ **E-Editor:** Liu JH

**Table 1 Comparison of general data between the two groups, *n* (%)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group** | ***n*** | **Male** | **Age (yr)** | **BMI (kg/m2)** | **Smoking** | **Drinking** |
| Observation | 240 | 168 (70.00) | 60.50 ± 9.28 | 23.30±5.44 | 103 (42.92) | 63 (26.25) |
| Control | 150 | 98 (65.33) | 59.22 ± 10.11 | 22.83 ± 6.50 | 56 (37.33) | 34 (22.67) |
| *t*/*χ*2 |  | 0.927 | 1.280 | 0.769 | 1.192 | 0.634 |
| *P* value |  | 0.336 | 0.201 | 0.442 | 0.275 | 0.426 |

BMI: Body mass index.

**Table 2 Comparison of serum fibroblast growth factor-23 and miR-208b levels in the two groups**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | ***n*** | **FGF-23 (ng/mL)** | **Relative expression of miR-208b** |
| Observation | 240 | 210.20 ± 89.60 | 5.30 ± 1.22 |
| Control | 150 | 110.04 ± 32.29 | 2.90 ± 0.88 |
| *t* |  | 13.162 | 20.926 |
| *P* value |  | 0.000 | 0.000 |

FGF: Fibroblast growth factor.

**Table 3 Comparison of serum fibroblast growth factor-23 and miR-208b in different subgroups of observation group**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Group** | ***n*** | **Man, *n* (%)** | **Age (yr)** | **FGF-23 (ng/mL)** | **Relative expression of miR-208b** | **LAD (mm)** | **LVEDD (mm)** | **LVESD (mm)** | **LVEF (%)** |
| Paroxysmal atrial fibrillation | 134 | 98 (73.13) | 61.02 ± 10.11 | 191.20 ± 65.59 | 4.88 ± 1.02 | 34.03 ± 4.02 | 50.03 ± 6.03 | 32.10 ± 5.58 | 53.30 ± 7.81 |
| Persistent atrial fibrillation | 106 | 70 (66.04) | 59.89 ± 9.92 | 234.22 ± 70.05 | 5.83 ± 1.00 | 38.81 ± 5.11 | 49.81 ± 5.82 | 32.01 ± 6.02 | 52.83 ± 8.10 |
| *t* |  | 1.419 | 0.867 | -4.896 | -7.227 | -8.112 | 0.285 | 0.120 | 0.455 |
| *P* value |  | 0.234 | 0.387 | 0.000 | 0.000 | 0.000 | 0.776 | 0.905 | 0.649 |

FGF: Fibroblast growth factor; LAD: Left atrial dimension; LVEDD: Left ventricular end diastolic diameter; LVEF: Left ventricular ejection fraction; LVESD: Left ventricular end-systolic diameter.

**Table 4 Comparison of serum fibroblast growth factor-23 and miR-208b in patients with and without a major cardiovascular event**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | ***n*** | **Man, *n* (%)** | **Age (yr)** | **FGF-23 (ng/mL)** | **Relative expression of miR-208b** |
| MACE | 58 | 43 (74.14) | 61.19 ± 10.54 | 243.30 ± 72.29 | 6.12 ± 1.12 |
| Non-MACE | 182 | 125 (68.68) | 62.28 ± 9.89 | 199.65 ± 71.43 | 5.04 ± 1.07 |
| *t* |  | 0.624 | -0.719 | 4.041 | 6.619 |
| *P* value |  | 0.43 | 0.473 | 0.000 | 0.000 |

FGF: Fibroblast growth factor; MACE: Major cardiovascular event.